|
Tuesday, 17 January 2012 22:40 |
|
PHILADELPHIA — Most research on glioblastoma development, a complicated tumor of the brain with a poor prognosis, has focused on the gene transcription level, but scientists suggest that post-transcriptional regulation could be equally or even more important. |
|
Read more...
|
|
Sunday, 15 January 2012 11:48 |
|
OHSU Knight Cancer Institute study results suggest that more patients than initially thought could potentially be treated with a new class of drugs, PARP inhibitors A constellation of defective proteins suspected in causing a malfunction in the body’s ability to repair its own DNA could be the link scientists need to prove a new class of drugs will be effective in treating a broad range of ovarian cancer patients, an Oregon Health & Science University Knight Cancer Institute study found. |
|
Read more...
|
|
Monday, 02 January 2012 23:07 |
|
Two recent studies distinguish cancer subtypes and provide promising new drug target. Grand Rapids, Mich. (December 29, 2011) – Two recent studies by Van Andel Research Institute scientists are providing a foundation for a more complete understanding of distinct kidney cancer subtypes, which could pave the way for better treatments. |
|
Read more...
|
|
Thursday, 22 December 2011 06:55 |
Cell-surface protein N-cadherin represents a promising therapeutic target for the treatment of pancreatic cancer, say researchers at Jefferson's Center for Translational Medicine |
|
Read more...
|
|
Wednesday, 21 December 2011 07:27 |
|
It is vital that the body's own immune system does not overreact. If its key players, the helper T cells, get out of control, this can lead to autoimmune diseases or allergies. An immune system overreaction against infectious agents may even directly damage organs and tissues. |
|
Read more...
|
|
Monday, 19 December 2011 06:43 |
|
WASHINGTON, D.C.-- In a major step that could revolutionize biomedical research, scientists have discovered a way to keep normal cells as well as tumor cells taken from an individual cancer patient alive in the laboratory — which previously had not been possible. Normal cells usually die in the lab after dividing only a few times, and many common cancers will not grow, unaltered, outside of the body. |
|
Read more...
|
|
Thursday, 15 December 2011 05:46 |
Test also differentiates between types and stages of lung cancer; study results for Metabolomx' colorimetric sensor array published in the Journal of Thoracic Oncology |
|
Read more...
|
|
Thursday, 08 December 2011 04:48 |
Researchers are slowly creating a blueprint for the molecular machine that keeps the pathogen alive and well in the acidic stew of the guts of half the world's population |
|
Read more...
|
|
Monday, 05 December 2011 05:40 |
|
Yale Cancer Center researchers have shown that a tiny genetic variation predicts chances of survival and response to treatment for patients with ovarian cancer. The findings, published in the journal Oncogene, provide new insights into the biology of a new class of cancer marker and suggest a genetic test may help guide the treatment of women with ovarian cancer. |
|
Read more...
|
|
Wednesday, 30 November 2011 05:10 |
Combination treatment with octreotide shows improved results in tumors associated with carcinoid syndrome HOUSTON -- Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome, according to researchers at The University of Texas MD Anderson Cancer Center. |
|
Read more...
|
|
|
Sunday, 15 January 2012 11:52 |
|
Scientists working at the Medical Research Council have identified changes in the patterns of sugar molecules that line pre-cancerous cells in the esophagus, a condition called Barrett's dysplasia, making it much easier to detect and remove these cells before they develop into esophageal cancer. These findings, reported in the journal Nature Medicine, have important implications for patients and may help to monitor their condition and prevent the development of cancer. |
|
Read more...
|
|
Sunday, 15 January 2012 11:46 |
|
A key protein potentially involved in regulating breast cancer progression has been identified by researchers at Clarkson University in Potsdam, N.Y. Led by professor Costel Darie, the team worked to identify the binding partner of Tumor Differentiating Factor (TDF), a pituitary hormone that had previously been shown to reduce cancer progression in breast cancer cells. |
|
Read more...
|
|
Sunday, 25 December 2011 05:07 |
Genetic analysis revises treatment recommendations related to thyroid cancer Friday, December 23, 2011, Cleveland: Cleveland Clinic researchers have discovered three genes that increase the risk of thyroid cancer, which is has the largest incidence increase in cancers among both men and women. |
|
Read more...
|
|
Wednesday, 21 December 2011 07:49 |
|
Apple chief executive officer Steve Jobs and author Christopher Hitchens, who both recently succumbed to their respective cancers, were among a select few cancer patients to have their entire genomes sequenced. Doctors were hoping to tailor each man's cancer treatment by identifying genetic mutations within the cancer that might be treatable with certain drugs — an approach known as personalized medicine. |
|
Read more...
|
|
Wednesday, 21 December 2011 07:04 |
Women who are at risk for breast cancer may also be at greater risk for heart disease TORONTO, ON., Dec. 20, 2011—Women who are at risk for breast cancer may also be at greater risk for heart disease, new research has found. The majority of women with hereditary breast and ovarian cancer have a mutated form of the BRCA1 or BRCA2 genes, which normally suppress the growth of breast and ovarian tumours. |
|
Read more...
|
|
Monday, 19 December 2011 06:26 |
Study indicates that drug toxicity may be related to genetic factors BUFFALO, N.Y. -- Will a drug used to treat childhood acute lymphoblastic leukemia and other pediatric cancers cause heart problems later in life? UB associate professor of pharmaceutical sciences, Javier G. Blanco, PhD, who sees his work as a bridge between research and clinical practice, has focused recent efforts on trying to answer this question. |
|
Read more...
|
|
Friday, 09 December 2011 04:55 |
|
TAMPA, Fla. (Dec. 8, 2011) - Women who have non-melanoma skin cancers are more likely to have smoked cigarettes compared to women without skin cancer, said researchers at Moffitt Cancer Center in Tampa, Fla., who published study results in a recent issue of Cancer Causes Control. |
|
Read more...
|
|
Thursday, 08 December 2011 04:06 |
|
JACKSONVILLE, Fla. — The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida. Their report, published online in Gynecologic Oncology, suggests that this combination (ixabepilone and sunitinib), might offer a much needed treatment option for women with advanced ovarian cancer. When caught at late stages, ovarian cancer is often fatal because it progressively stops responding to the chemotherapy drugs used to treat it. |
|
Read more...
|
|
Monday, 05 December 2011 05:24 |
Nature Medicine publishes a pioneering study about a protein that regulates the expression of hundreds of genes that have a crucial role in the progression of pancreatic cancer, gliomas and possibly many other kinds of tumor. |
|
Read more...
|
|
Wednesday, 30 November 2011 05:04 |
|
Newly published research explores the role of 14-3-3σ in tumour suppression New research out of McGill University's Goodman Cancer Research Centre provides compelling new evidence that a gene known as 14-3-3σ plays a critical role in halting breast cancer initiation and progression. The study, led by the Dept. of Biochemistry's William J. Muller, will be published online today in the journal Cancer Discovery. |
|
Read more...
|
|